Overview

Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict which patients will respond to treatment. PURPOSE: This laboratory study is looking at prognostic factors in patients receiving tegafur-uracil for stage II colon cancer that was completely removed by surgery.

Details

Lead Sponsor:

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Translational Research Informatics Center, Kobe, Hyogo, Japan

Collaborator:

Tokyo Medical and Dental University

Treatments:

Tegafur